# Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease

> **NCT00911807** · PHASE2 · COMPLETED · sponsor: **Ever Neuro Pharma GmbH** · enrollment: 217 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Cerebrolysin + donepezil
- **DRUG:** Cerebrolysin + placebo
- **DRUG:** Donepezil + placebo

## Key facts

- **NCT ID:** NCT00911807
- **Lead sponsor:** Ever Neuro Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2009-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911807, "Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00911807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*